Preparation of (188Re) Re-AEDP and its biodistribution studies

Appl Radiat Isot. 2000 Dec;53(6):993-7. doi: 10.1016/s0969-8043(99)00271-7.

Abstract

The synthesis of the Re (V) complex and preparation of 188Re-AEDP are described using 188Re which was obtained from the alumina-based 188W/188Re generator. Dependence of the radiolabeling yields of 188Re-AEDP on reducing agent concentration, AEDP concentration, pH and addition of carrier was examined. In the case of optimum conditions, the radiolabeling yields of 188Re-AEDP were 92-93% for carrier-free 188Re and 95-98% for carrier-added 188Re. The stability of 188Re-AEDP at pH approximately 6 was studied and it is found that the carrier has a significant effect on the stability of 188Re-AEDP. The biodistribution of carrier-free and carrier-added 188Re-labelled compounds in rats was also measured. The results show that 188Re (carrier-added)-AEDP is a potential bone palliation radiopharmaceutical due to its high skeletal uptake, rapid blood clearance and relatively low soft tissue absorption.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bone Neoplasms / radiotherapy
  • Bone Neoplasms / secondary
  • Diphosphonates / isolation & purification*
  • Diphosphonates / pharmacokinetics*
  • Diphosphonates / therapeutic use
  • Drug Carriers
  • Drug Stability
  • Female
  • Hydrogen-Ion Concentration
  • Palliative Care
  • Radiopharmaceuticals / isolation & purification*
  • Radiopharmaceuticals / pharmacokinetics*
  • Radiopharmaceuticals / therapeutic use
  • Rats
  • Rhenium / isolation & purification*
  • Rhenium / pharmacokinetics*
  • Rhenium / therapeutic use
  • Tin Compounds
  • Tissue Distribution

Substances

  • 1-aminoethylene diphosphonic acid
  • Diphosphonates
  • Drug Carriers
  • Radiopharmaceuticals
  • Tin Compounds
  • stannous chloride
  • Rhenium